# Safety of OMS103HP in Patients Undergoing Anterior Cruciate Ligament (ACL) Reconstruction

> **NCT00245271** · PHASE3 · COMPLETED · sponsor: **Omeros Corporation** · enrollment: 480 (estimated)

## Conditions studied

- Anterior Cruciate Ligament Reconstruction

## Interventions

- **DRUG:** OMS103HP
- **DRUG:** Vehicle

## Key facts

- **NCT ID:** NCT00245271
- **Lead sponsor:** Omeros Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-10
- **Primary completion:** 2010-03
- **Final completion:** 2011-03
- **Target enrollment:** 480 (ESTIMATED)
- **Last updated:** 2011-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00245271

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00245271, "Safety of OMS103HP in Patients Undergoing Anterior Cruciate Ligament (ACL) Reconstruction". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00245271. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*